Nurix presents data on bexobrutideg for chronic urticaria at dermatology meeting

May 14, 2026 4:05 PM

Nurix Therapeutics (NASDAQ: NRIX) presented preclinical and Phase 1 data for bexobrutideg (NX-5948) in chronic spontaneous urticaria at the 2026 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found